Result of AGM
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your STX notes
London, UK, 18 June 2026: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company specialising in iron deficiency with or without anemia ("ID/IDA"), announces the voting results for each resolution set out in the Notice of Annual General Meeting 2026. The Board reports that all resolutions were passed: 1 to 12 passed as ordinary resolutions and 13 and 14 passed as special resolutions.
The following table shows the votes cast on each resolution:
| VOTES FOR | % | VOTES AGAINST | % | WITHHELD VOTES | |
|---|---|---|---|---|---|
| Resolution 1 | 663,423,759 | 99.99% | 83,973 | 0.01% | 612,706 |
| Resolution 2 | 663,165,096 | 99.96% | 259,840 | 0.04% | 695,502 |
| Resolution 3 | 662,822,843 | 99.91% | 602,093 | 0.09% | 695,502 |
| Resolution 4 | 663,131,934 | 99.96% | 267,835 | 0.04% | 720,669 |
| Resolution 5 | 662,884,358 | 99.92% | 540,585 | 0.08% | 695,495 |
| Resolution 6 | 663,146,757 | 99.96% | 253,012 | 0.04% | 720,669 |
| Resolution 7 | 662,771,376 | 99.91% | 628,393 | 0.09% | 720,669 |
| Resolution 8 | 663,346,163 | 99.97% | 189,245 | 0.03% | 585,030 |
| Resolution 9 | 661,191,218 | 99.65% | 2,342,764 | 0.35% | 586,456 |
| Resolution 10 | 660,806,346 | 99.56% | 2,944,366 | 0.44% | 369,726 |
| Resolution 11 | 660,769,857 | 99.55% | 2,978,561 | 0.45% | 372,020 |
| Resolution 12 | 658,773,200 | 99.24% | 5,058,591 | 0.76% | 288,647 |
| Resolution 13 | 658,492,989 | 99.21% | 5,225,392 | 0.79% | 402,057 |
| Resolution 14 | 658,549,598 | 99.26% | 4,920,741 | 0.74% | 650,099 |
Notes:
- Number of shares in issue 1,069,524,125.
- Details of the votes received on the resolutions are available on the Company's website:
- Shield Therapeutics plc LEI: 213800G74QWY15FC3W71.
Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR® has the potential to meet an important unmet medical need for both physicians and patients and is now the leading #1 branded prescription oral iron the market today (data source - IQVIA Xponent PlanTrak).
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.